DDInter1826 DDInter1132
A sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Mecasermin rinfabate is approved for severe primary insulin-like growth factor (IGF) deficiency or in patients with GH gene deletion who have developed antibodies to growth hormone (GH). Mecasermin rinfabate is similar to in that both drugs contain recombinant DNA origin insulin-like growth factor 1 (IGF-1). Mecasermin rinfabate however, is already bound to recombinant DNA origin insulin-like growth factor binding protein 3 (IGFBP-3). The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent <500 patients worldwide. Mecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005. In 2007 Insmed withdrew their application for a marketing authorization with The European Medicines Agency.
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) binds {v} (Gene) ABCC8
ABCC8 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) causes {v} (Side Effect) Hypoglycaemia
Hypoglycaemia {u} (Side Effect) is caused by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin degludec
Insulin degludec {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) is included by {v} (Pharmacologic Class) Sulfonylurea Compounds
Sulfonylurea Compounds {u} (Pharmacologic Class) includes {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide {u} (Compound) downregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is downregulated by {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mecasermin rinfabate
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) binds ABCC8 (Gene) and ABCC8 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) causes Hypoglycaemia (Side Effect) and Hypoglycaemia (Side Effect) is caused by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) is included by Sulfonylurea Compounds (Pharmacologic Class) and Sulfonylurea Compounds (Pharmacologic Class) includes Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate
Tolazamide (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Mecasermin rinfabate